Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) Gross Margin (2016 - 2025)

Historic Gross Margin for Abvc Biopharma (ABVC) over the last 9 years, with Q3 2025 value amounting to 100.0%.

  • Abvc Biopharma's Gross Margin rose 800.0% to 100.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 300.74%, marking a year-over-year increase of 2282000.0%. This contributed to the annual value of 99.85% for FY2024, which is 1980000.0% up from last year.
  • Per Abvc Biopharma's latest filing, its Gross Margin stood at 100.0% for Q3 2025, which was up 800.0% from 100.0% recorded in Q4 2024.
  • Abvc Biopharma's 5-year Gross Margin high stood at 100.0% for Q4 2024, and its period low was 6329.84% during Q4 2023.
  • Its 5-year average for Gross Margin is 373.78%, with a median of 92.61% in 2022.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -63847800bps in 2023, then soared by 64298400bps in 2024.
  • Abvc Biopharma's Gross Margin (Quarter) stood at 10.31% in 2021, then soared by 433bps to 54.94% in 2022, then tumbled by -11622bps to 6329.84% in 2023, then skyrocketed by 102bps to 100.0% in 2024, then changed by 0bps to 100.0% in 2025.
  • Its last three reported values are 100.0% in Q3 2025, 100.0% for Q4 2024, and 99.92% during Q3 2024.